Business Description
Broncus Holding Corp
ISIN : KYG1609T1022
Total Employee Number:
191Compare
Compare
Traded in other countries / regions
02216.Hong KongBRNHF.USA IPO Date
2021-09-24Description
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 404.36 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.49 | |||||
Beneish M-Score | 4.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -72.9 | |||||
3-Year EBITDA Growth Rate | 14 | |||||
3-Year EPS without NRI Growth Rate | 13.1 | |||||
3-Year FCF Growth Rate | 31.5 | |||||
3-Year Book Growth Rate | -13.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 394.86 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.06 | |||||
9-Day RSI | 58.4 | |||||
14-Day RSI | 52.61 | |||||
3-1 Month Momentum % | -25.56 | |||||
6-1 Month Momentum % | -60.36 | |||||
12-1 Month Momentum % | -77.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.43 | |||||
Quick Ratio | 14.96 | |||||
Cash Ratio | 13.51 | |||||
Days Inventory | 765.28 | |||||
Days Sales Outstanding | 700.33 | |||||
Days Payable | 35.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.5 | |||||
Shareholder Yield % | 6.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 6.34 | |||||
Operating Margin % | -1240.67 | |||||
Net Margin % | -996.32 | |||||
EBITDA Margin % | -903.59 | |||||
FCF Margin % | -516.96 | |||||
OCF Margin % | -499.1 | |||||
ROE % | -12.03 | |||||
ROA % | -11.54 | |||||
ROIC % | -64.78 | |||||
3-Year ROIIC % | -364.2 | |||||
ROC (Joel Greenblatt) % | -261.85 | |||||
ROCE % | -12.01 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 22.59 | |||||
PB Ratio | 0.31 | |||||
Price-to-Tangible-Book | 0.32 | |||||
EV-to-EBIT | 3.02 | |||||
EV-to-EBITDA | 3.33 | |||||
EV-to-Revenue | -30.07 | |||||
EV-to-Forward-Revenue | 16.11 | |||||
EV-to-FCF | 5.82 | |||||
Price-to-GF-Value | 4.37 | |||||
| Price-to-Net-Current-Asset-Value | 0.42 | |||||
| Price-to-Net-Cash | 0.48 | |||||
Earnings Yield (Greenblatt) % | 33.11 | |||||
FCF Yield % | -21.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Broncus Holding Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 14.27 | ||
| EPS (TTM) (HK$) | -0.313 | ||
| Beta | 0.7019 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.19 | ||
| Volatility % | 52.91 | ||
| 14-Day RSI | 52.61 | ||
| 14-Day ATR (HK$) | 0.052254 | ||
| 20-Day SMA (HK$) | 0.6225 | ||
| 12-1 Month Momentum % | -77.36 | ||
| 52-Week Range (HK$) | 0.53 - 3.72 | ||
| Shares Outstanding (Mil) | 527.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Broncus Holding Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Broncus Holding Corp Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-28 | 0.65 (-0.77%) | ||
| General meeting for 2025 | 2026-05-14 10:00 | 1.00 (-3.85%) | ||
| Annual report for 2025 | 2026-04-20 | 1.34 (-4.29%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 3.04 (-2.56%) | ||
| General meeting for 2024 | 2025-05-16 10:00 | 2.20 (-3.93%) | ||
| Annual report for 2024 | 2025-04-24 | 1.58 (+1.94%) |
Show
Entries
Broncus Holding Corp Frequently Asked Questions
What is Broncus Holding Corp(HKSE:02216)'s stock price today?
The current price of HKSE:02216 is HK$0.66. The 52 week high of HKSE:02216 is HK$3.72 and 52 week low is HK$0.53.
When is next earnings date of Broncus Holding Corp(HKSE:02216)?
The next earnings date of Broncus Holding Corp(HKSE:02216) is 2027-02-28 Est..
Does Broncus Holding Corp(HKSE:02216) pay dividends? If so, how much?
Broncus Holding Corp(HKSE:02216) does not pay dividend.
Press Release
Articles on Broncus Holding Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers